MapKure, LLC Report issue

For profit Phase 1
Founded: Beijing China (2019)

Organization Overview

First Clinical Trial
2020
NCT04249843
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

MapKure, LLC

Active Ingredients

Drugs in Phase 1 Trials (1)

bgb-3245 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1